---
schema_version: "secwatch.filing_event.v1"
accession: "0001493152-24-031471"
form_type: "8-K"
ticker: "PAVM"
cik: "0001624326"
company_name: "PAVmed Inc."
filed_at: "2024-08-13T23:59:59+00:00"
generated_at: "2026-05-31T09:43:46.008104+00:00"
event_type: "earnings"
sentiment: "neutral"
materiality_score: 0.65
calibrated_materiality_score: 0.65
confidence: "high"
source: SEC EDGAR
---

# PAVmed Q2 GAAP net loss $10.9M; Lucid EsoGuard test volume record 3,147 (up 31% QoQ)

## Summary
- Q2 revenue $1.0M from EsoGuard test; GAAP net loss attributable to common $10.9M ($1.19/sh).
- Adjusted non-GAAP loss $7.7M ($0.84/sh). Cash and equivalents $25.5M at June 30, 2024.
- Lucid commercial EsoGuard tests: 3,147 in Q2 (single-quarter record), +31% sequential, +44% YoY.
- Lucid held productive meeting with CMS MAC Palmetto GBA's MolDX program for EsoGuard coverage.
- Veris launched pilot with Ohio State's James Cancer Hospital; actively pursuing independent financing.

## SEC filing metadata
- accession: 0001493152-24-031471
- form_type: 8-K
- ticker: PAVM
- cik: 0001624326
- company_name: PAVmed Inc.
- filed_at: 2024-08-13T23:59:59+00:00
- event_type: earnings
- sentiment: neutral
- materiality_score: 0.65
- calibrated_materiality_score: 0.65
- confidence: high
- sec_items: 2.02, 7.01, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1624326/000149315224031471/0001493152-24-031471-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1624326/000149315224031471/form8-k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001493152-24-031471
- JSON: https://secwatch.observer/filing/0001493152-24-031471.json
- Plain text: https://secwatch.observer/filing/0001493152-24-031471.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.